CCX771
| Drug Information | |||
|---|---|---|---|
| Image | |||
| Identifiers
CAS Number ATC Code PubChem DrugBank ChemSpider ID UNII KEGG ChEBI ChEMBL IUPAC Name |
Chemical Data
C H N O Molecular Weight | ||
CCX771 is an investigational drug that acts as a selective antagonist of the chemokine receptor CCR9. It is being studied for its potential therapeutic effects in treating inflammatory diseases, particularly those involving the gastrointestinal tract, such as Crohn's disease and ulcerative colitis.
Mechanism of Action[edit | edit source]
CCX771 functions by inhibiting the interaction between the chemokine receptor CCR9 and its ligand, CCL25. This interaction is crucial in the migration of T cells to the small intestine, where they can contribute to inflammatory processes. By blocking this pathway, CCX771 aims to reduce the recruitment of inflammatory cells to the gut, thereby alleviating symptoms associated with inflammatory bowel diseases.
Clinical Development[edit | edit source]
CCX771 is currently in the investigational stages, with several clinical trials assessing its efficacy and safety. Early studies have shown promise in reducing inflammation and improving clinical outcomes in patients with moderate to severe Crohn's disease. However, further research is needed to fully establish its therapeutic potential and safety profile.
Pharmacokinetics[edit | edit source]
The pharmacokinetic properties of CCX771, including its absorption, distribution, metabolism, and excretion, are still under investigation. Preliminary data suggest that it is administered orally and has a favorable bioavailability profile, but detailed studies are required to confirm these findings.
Potential Side Effects[edit | edit source]
As with any investigational drug, the safety profile of CCX771 is not yet fully understood. Common side effects observed in early trials include mild gastrointestinal disturbances, headache, and fatigue. Serious adverse effects have not been widely reported, but ongoing studies are monitoring for any potential risks.
Research and Future Directions[edit | edit source]
Research on CCX771 is ongoing, with a focus on optimizing its therapeutic efficacy and minimizing side effects. Future studies may explore its use in other inflammatory conditions beyond the gastrointestinal tract, as well as its long-term safety and effectiveness.
Also see[edit | edit source]
Template:Chemokine receptor antagonists
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
